Julia Glade Bender
Overview
Explore the profile of Julia Glade Bender including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Green A, Minard C, Liu X, Safgren S, Pinkney K, Harris L, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39998852
Background: Selinexor is a first-in-class, central nervous system (CNS)-penetrant, oral inhibitor of exportin 1 (XPO1), the main nuclear exporter of many key tumor suppressors. We report a phase 1 trial...
2.
Pearson A, Mueller S, Filbin M, Grill J, Hawkins C, Jones C, et al.
Eur J Cancer
. 2025 Jan;
217:115230.
PMID: 39854822
Fewer than 10 % of children with diffuse midline glioma (DMG) survive 2 years from diagnosis. Radiation therapy remains the cornerstone of treatment and there are no medicinal products with...
3.
Bird N, Scobie N, Berlanga P, Blanc P, Buenger V, Campbell-Hewson Q, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2449239.
PMID: 39641924
Importance: In poor-prognosis children's cancers, new therapies may carry fresh hope for patients and parents. However, there is an absolute requirement for any new therapy to be properly evaluated to...
4.
Daukshus N, Avutu V, Long Sarro E, Kinnaman M, Slotkin E, Thornton K, et al.
J Adolesc Young Adult Oncol
. 2024 Jul;
PMID: 39008434
Limited guidance exists on streamlining cancer therapy for adolescent and young adult (AYA) patients 15-39 years of age, as much of the current data are extrapolated from pediatric or adult...
5.
Kanukollu S, Spatz K, Lavery J, Glade Bender J, Mauguen A, Mathew S
Pediatr Blood Cancer
. 2024 Jan;
71(4):e30882.
PMID: 38267822
NK-1 receptor antagonists (NK1-RA) are key agents for chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Current pediatric practice guidelines recommend the use of intravenous fosaprepitant...
6.
Pearson A, Federico S, Gatz S, Ortiz M, Lesa G, Scobie N, et al.
Eur J Cancer
. 2023 Jul;
190:112950.
PMID: 37441939
DNA damage response inhibitors have a potentially important therapeutic role in paediatric cancers; however, their optimal use, including patient selection and combination strategy, remains unknown. Moreover, there is an imbalance...
7.
Moreno L, Dubois S, Glade Bender J, Mauguen A, Bird N, Buenger V, et al.
J Clin Oncol
. 2023 Apr;
41(18):3408-3422.
PMID: 37015036
Purpose: There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious...
8.
Doe-Tetteh S, Camp S, Reales D, Crowdis J, Noronha A, Wolff B, et al.
Clin Cancer Res
. 2023 Mar;
29(13):2445-2455.
PMID: 36862133
Purpose: To overcome barriers to genomic testing for patients with rare cancers, we initiated a program to offer free clinical tumor genomic testing worldwide to patients with select rare cancer...
9.
ODonohue T, Farouk Sait S, Glade Bender J
Curr Opin Pediatr
. 2022 Nov;
35(1):41-47.
PMID: 36377257
Purpose Of Review: The fields of precision medicine and cancer genomics in pediatric oncology are rapidly evolving. Novel diagnostic tools are critical in refining cancer diagnoses, stratifying patient risk, and...
10.
Pearson A, Allen C, Fangusaro J, Hutter C, Witt O, Weiner S, et al.
Eur J Cancer
. 2022 Nov;
177:120-142.
PMID: 36335782
As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK pathway inhibitors are being...